TET2 is required for Type I IFN-mediated inhibition of bat-origin swine acute diarrhea syndrome coronavirus

J Med Virol. 2022 Jul;94(7):3251-3256. doi: 10.1002/jmv.27673. Epub 2022 Mar 7.

Abstract

Swine acute diarrhea syndrome coronavirus (SADS-CoV) is a newly discovered bat-origin coronavirus with fatal pathogenicity for neonatal piglets. There is no vaccine to prevent SADS-CoV infection or clinically approved drugs targeting SADS-CoV. Therefore, unraveling cellular factors that regulate SADS-CoV for cell entry is critical to understanding the viral transmission mechanism and provides a potential therapeutic target for SADS-CoV cure. Here, we showed that Type I interferon (IFN-I) pretreatment potently blocks SADS-CoV entry into cells using lentiviral pseudo-virions as targets whose entry is driven by the SADS-CoV Spike glycoprotein. IFN-I-mediated inhibition of SADS-CoV entry and replication was dramatically impaired in the absence of TET2. These results suggest TET2 is found to serve as a checkpoint of IFN-I-meditated inhibition on the cell entry of SADS-CoV, and our discovery might constitute a novel treatment option to combat against SADS-CoV.

Keywords: coronavirus; local infection/replication/spread pathogenesis; zoonoses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alphacoronavirus* / physiology
  • Animals
  • Chiroptera*
  • DNA-Binding Proteins / physiology
  • Dioxygenases* / physiology
  • Humans
  • Interferon Type I
  • Spike Glycoprotein, Coronavirus

Substances

  • DNA-Binding Proteins
  • Interferon Type I
  • Spike Glycoprotein, Coronavirus
  • Dioxygenases
  • TET2 protein, human

Supplementary concepts

  • Swine acute diarrhea syndrome coronavirus